
News|Articles|November 26, 2013
3M Licenses Transdermal Patch for Stada
Author(s)Pharmaceutical Technology Editors
Stada licenses 3M's transdermal technology for a fentanyl patch.
Advertisement
The 3M Patent, which was granted on March 20, 2013, enables a transdermal drug delivery device designed to deliver a therapeutically effective amount of fentanyl across the skin of a patient. The matrix device is configured by incorporating fentanyl into an adhesive matrix made of a copolymer containing alkyl acrylate and other monomers.
Source:
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
A Capsule-in-Capsule Platform for Multi-Phase Release of Liquid and Solid Formulations
2
Europe Tried to Ban Generative AI From Critical GMP. The Ban May Not Survive. It Does Not Matter.
3
Q&A: Why Is Halo Pharma Expanding Into Sterile Injectables Now?
4
What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers?
5




